Trying to figure out what to do with Intellia Therapeutics stock? You’re definitely not alone. After all, this is a company that’s been on quite the rollercoaster lately. Over just the past week, ...

As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.

As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in coming days, analysts and especially investors will keep their eyes on whether the ...

New to Growth Stocks? Here's 1 Every Investor Should Have on Their Radar. CRISPR Therapeutics has an approved gene-editing ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

Prosper Junior Bakiny has positions in Alphabet, Amazon, and Vertex Pharmaceuticals. The Motley Fool has positions in and ...

As a cornerstone of Indian agriculture and a critical contributor to the national economy and food security across Asia, rice presents both enormous opportunities and pressing challenges. Modern gene ...

The latest in a trend of companies stepping back from cell and gene therapies amid regulatory uncertainty and manufacturing ...

Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile--The AATD ...

Algen Biotechnologies partners with AstraZeneca in a $555 million deal to advance AI-driven CRISPR drug discovery and novel ...

From curing inherited disorders to modifying crops and even animal species, gene editing has moved from science fiction to daily reality—raising questions science can’t ignore.

Ark Invest bought shares of Alibaba, Intellia Therapeutics, and Baidu on Monday. Alibaba and Baidu are surging Chinese e-commerce stocks that have emerged as AI plays. Intellia shares have almost ...